Heterogeneity of cost estimates in health economic evaluation research. A systematic review of stress urinary incontinence studies

Sandra Zwolsman,Joost Daams,Arnoud Kastelein,B C Opmeer,Jan-Paul Roovers

doi:10.1007/s00192-018-3814-0

Abstract

Introduction and hypothesisThere is increased demand for an international overview of cost estimates and insight into the variation affecting these estimates. Understanding of these costs is useful for cost-effectiveness analysis (CEA) research into new treatment modalities and for clinical guideline development.MethodsA systematic search was conducted in Ovid MEDLINE & other non-indexed materials and Ovid Embase for articles published between 1995 and 2017. The National Health Service Economic Evaluation Database (NHS-EED) filter and the McMaster sensitive therapy filter were combined with a bespoke search strategy for stress urinary incontinence (SUI). We extracted unit cost estimates, assessed variability and methodology, and determined transferability.ResultsWe included 37 studies in this review. Four hundred and eighty-two cost estimates from 13 countries worldwide were extracted. Descriptive analysis shows that hospital stay in gynecology ranged between €82 and €1,292 per day. Costs of gynecological consultation range from €30 in France to €158 in Sweden. In the UK, costs are estimated at €228 per hour. Costs of a tension-free vaginal tape (TVT) device range from €431 in Finland to €994 in Canada. TVT surgery per minute costs €25 in France and €82 in Sweden. Total costs of TVT range from €1,224 in Ireland to €5,809 for inpatient care in France. Variation was explored.ConclusionsHeterogeneity was observed in cost estimates for all units at all levels of health care. CEAs of SUI interventions cannot be interpreted without bias when the base of these analyses—namely costs—cannot be compared and generalized.

Highlights

Introduction and hypothesisThere is increased demand for an international overview of cost estimates and insight into the variation affecting these estimates
Urinary incontinence is a common condition in women with annual costs of nearly 10 billion euros in both direct and indirect costs in Europe [1]. Most of these women suffer from stress urinary incontinence (SUI) [2, 3]
Insight into these costs is useful for costeffectiveness research into new treatment modalities and for clinical guideline development

Summary

Introduction

There is increased demand for an international overview of cost estimates and insight into the variation affecting these estimates. Understanding of these costs is useful for cost-effectiveness analysis (CEA) research into new treatment modalities and for clinical guideline development. The costs for diagnosis, treatment, and follow-up of patients with SUI differ among countries. Insight into these costs is useful for costeffectiveness research into new treatment modalities and for clinical guideline development. Economic data from cost-effectiveness studies shows great variability [4], which prevents the reliable use of these data

Objectives

Results

Conclusion